TLR4选择性抑制改变骨髓微环境从而影响多发性骨髓瘤细胞生长
多发性骨髓瘤(MM)患者骨髓间充质干细胞(MSCs)中Toll样受体4(TLR4)表达高于健康供者,且随疾病分期演变。TLR4激动剂可上调MM MSCs的CD54和IL-6表达;TLR4拮抗剂在体外以IL-6依赖方式减少MM MSCs对MM细胞生长的支持,并在Vk*MYC小鼠模型中通过改变早期疾病阶段延迟MM发展。
要点
- MM患者MSCs的TLR4表达高于健康供者,且与疾病分期平行演变。
- TLR4激动剂上调MM MSCs的CD54和IL-6,参与MSC-MM细胞交互。
- TLR4拮抗剂以IL-6依赖方式减少MM MSCs支持MM细胞生长,并延迟Vk*MYC小鼠MM发展。
核心结论
- 特异性靶向TLR4信号通路可能通过改变病理骨髓微环境干预MM疾病发展。
研究设计与样本
- 比较MM患者与健康供者MSCs的TLR4基因表达,并用TLR4激动剂处理原代MSCs。
- 体外采用MSC-MM细胞共培养,体内采用Vk*MYC小鼠模型评估TLR4拮抗剂联合或不联合常规治疗。
主要发现
- MM MSCs的TLR4基因表达高于健康供者MSCs,且TLR4表达随MM疾病分期演变。
- TLR4激动剂增加原代MSCs的CD54和IL-6表达。
- TLR4选择性抑制以IL-6依赖方式降低MM MSCs支持MM细胞生长的能力。
- TLR4拮抗剂在Vk*MYC小鼠中通过改变早期疾病阶段延迟MM发展。
临床怎么用
- TLR4信号轴可能作为靶向骨髓微环境的MM治疗新方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone marrow (BM) mesenchymal stromal cells (MSCs) are abnormal in multiple myeloma (MM) and play a critical role by promoting growth, survival, and drug resistance of MM cells. We observed higher Toll-like receptor 4 (TLR4) gene expression in MM MSCs than in MSCs from healthy donors. At the clinical level, we highlighted that TLR4 expression in MM MSCs evolves in parallel with the disease stage. Thus, we reasoned that the TLR4 axis is pivotal in MM by increasing the protumor activity of MSCs. Challenging primary MSCs with TLR4 agonists increased the expression of CD54 and interleukin-6 (IL-6), 2 factors directly implicated in MM MSC-MM cell crosstalk. Then, we evaluated the therapeutic efficacy of a TLR4 antagonist combined or not with conventional treatment in vitro with MSC-MM cell coculture and in vivo with the Vk*MYC mouse model. Selective inhibition of TLR4 specifically reduced the MM MSC ability to support the growth of MM cells in an IL-6-dependent manner and delayed the development of MM in the Vk*MYC mouse model by altering the early disease phase in vivo. For the first time, we demonstrate that specific targeting of the pathological BM microenvironment via TLR4 signaling could be an innovative approach to alter MM pathology development.
引用
- Lemaitre L, Hamaidia M, Descamps JG, et al. Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. Blood Adv. 2022. PMID: 34714910. doi:10.1182/bloodadvances.2020003704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。